One hundred years have passed since Felix Hoffman, working at Bayer Industries, reported the successful synthesis of acetylsalicylic acid as the first nonsteroidal antiinflammatory drug (NSAID).¹,² At the suggestion of Hermann Dreser, Bayer's chief pharmacologist at the time,³ the compound was called “aspirin” and was purported to represent a convenient mechanism for the delivery of salicylic acid in the treatment of rheumatic diseases, menstrual pain, and fever.² Approximately 40 years elapsed before Douthwaite and Lintott⁴ provided endoscopic evidence that aspirin could cause gastric mucosal damage. Numerous reports have corroborated this observation,⁵–⁸ and the introduction of more potent agents . . .